Product Name	CD86
Chinese Name	CD86抗体
Alias	CD28LG2; FUN1; LAB72; Activation B7 2 antigen; Activation B7-2 antigen 3; CD86_HUMAN; Activation B7-2 antigen; Activation B72 antigen; B lymphocyte activation antigen B7 2; B lymphocyte activation antigen B72; B-lymphocyte activation antigen B7-2 2; B-lymphocyte activation antigen B7-2; B7 2; B7 2 antigen; B7; B7-2; B7.2; B70; B72 antigen; BU63; CD 86; CD28 antigen ligand 2 2; CD28 antigen ligand 2; Cd28l2; CD28LG2; CD86 antigen (CD28 antigen ligand 2, B7-2 antigen) 1, 2; CD86 antigen; CD86 molecule; CLS1; CTLA 4 counter receptor B7 2; CTLA 4 counter receptor B7.2; CTLA-4 counter-receptor B7.2 2, 3; CTLA4 counter receptor B72; Early T-cell costimulatory molecule 1; ETC-1; FUN 1; LAB72; Ly-58; Ly58; MB7; MB7-2; Membrane glycoprotein; MGC34413; T lymphocyte activation antigen CD86; T-lymphocyte activation antigen CD86; TS/A-2.
literatures	Specific References  (63)     |     SL1035R has been referenced in 63 publications. [IF=20.722] Meng Lin. et al. CRISPR-based in situ engineering tumor cells to reprogram macrophages for effective cancer immunotherapy. Nano Today. 2022 Feb;42:101359  IF ;  Mouse.   PubMed:10.1016/j.nantod.2021.101359 [IF=15.304] Xuan Li. et al. ROS-responsive hydrogel coating modified titanium promotes vascularization and osteointegration of bone defects by orchestrating immunomodulation. BIOMATERIALS. 2022 Aug;287:121683  IHC ;  Rat.   PubMed:35870263 [IF=14.919] Singh, Alok Kumar. et al. Re-engineered BCG overexpressing cyclic di-AMP augments trained immunity and exhibits improved efficacy against bladder cancer. Nat Commun. 2022 Feb;13(1):1-16  IHC ;  Mouse.   PubMed:10.1038/s41467-022-28509-z [IF=14.593] Bin Wang. et al. Targeted delivery of a STING agonist to brain tumors using bioengineered protein nanoparticles for enhanced immunotherapy. Bioact Mater. 2022 Mar;:  IF ;  Mouse.   PubMed:35386310 [IF=12.91] Kai Ye. et al. An armed oncolytic virus enhances the efficacy of tumor-infiltrating lymphocyte therapy by converting tumors to artificial antigen presenting cells in situ. MOL THER. 2022 Jun;:  IHC ;  Mouse.   PubMed:35715953 [IF=11.092] Kun Xu. et al. Functional Titanium Substrates Synergetic Photothermal Therapy for Enhanced Antibacterial and Osteogenic Performance via Immunity Regulation. ADV HEALTHC MATER. 2023 Mar;:2300494  ICC,FCM,IHC ;  Mouse.   PubMed:36929688 [IF=10.435] Mei, Jiawei. et al. An injectable photo-cross-linking silk hydrogel system augments diabetic wound healing in orthopaedic surgery through spatiotemporal immunomodulation. J NANOBIOTECHNOL. 2022 Dec;20(1):1-22  IF ;  Mouse.   PubMed:35568914 [IF=10.317] Yang G et al. A multifunctional anti-inflammatory drug that can specifically target activated macrophages, massively deplete intracellular H 2 O 2, and produce large amounts CO for a highly efficient treatment of osteoarthritis. Biomaterials . 2020 Oct;255:120155.  ICF ;  Mouse.   PubMed:32554130 [IF=10.317] Yang G et al. A multifunctional anti-inflammatory drug that can specifically target activated macrophages, massively deplete intracellular H2O2, and produce large amounts CO for a highly efficient treatment of osteoarthritis. Biomaterials. 2020 Oct;255:120155.  ICF ;  Mouse.   PubMed:32554130 [IF=9.995] Yuqiu Xu. et al. Tumor-infiltrated activated B cells suppress liver metastasis of colorectal cancers. CELL REP. 2022 Aug;40:111295  IF ;  Human.   PubMed:36044847 [IF=9.918] Daijun Zhou. et al. An injectable miR181a-IFI6 nanoparticles promote high-quality healing of radiation-induced skin injury. MATER TODAY ADV. 2022 Aug;15:100267  FC ;  Human.   PubMed:10.1016/j.mtadv.2022.100267 [IF=9.207] Li Yin. et al. G6PD activation in TNBC cells induces macrophage recruitment and M2 polarization to promote tumor progression. CELL MOL LIFE SCI. 2023 Jun;80(6):1-20  WB ;  Human.   PubMed:37237244 [IF=8.947] Junpeng Chen. et al. An all-in-one CO gas therapy-based hydrogel dressing with sustained insulin release, anti-oxidative stress, antibacterial, and anti-inflammatory capabilities for infected diabetic wounds. ACTA BIOMATER. 2022 Apr;:  Other ;  Other.   PubMed:35500813 [IF=8.897] Liu, Houli. et al. Immunomodulatory hybrid bio-nanovesicle for self-promoted photodynamic therapy. Nano Res. 2022 Feb;:1-10  WB ;  Mouse.   PubMed:10.1007/s12274-021-4050-3 [IF=8.352] Ye Hea et al. Improved osteointegration by SEW2871-encapsulated multilayers on micro-structured titanium via macrophages recruitment and immunomodulation. Applied Materials Today 20 (2020) 100673  IHC/IF ;  Rat/Mouse.   PubMed:10.1016/j.apmt.2020.100673 [IF=7.525] Ndzie Noah Marie Louise. et al. Estrogen downregulates CD73/adenosine axis hyperactivity via adaptive modulation PI3K/Akt signaling to prevent myocarditis and arrhythmias during chronic catecholamines stress. CELL COMMUN SIGNAL. 2023 Dec;21(1):1-11  IHC ;  Mouse.   PubMed:36823590 [IF=7.367] Yitian Du. et al. Engineered Microglia Potentiate the Action of Drugs against Glioma Through Extracellular Vesicles and Tunneling Nanotubes. 2021 Feb 28  IF,IHC ;  Mouse.   PubMed:33644993 [IF=7.242] Tong Shen. et al. Sulfated chitosan rescues dysfunctional macrophages and accelerates wound healing in diabetic mice. Acta Biomater. 2020 Nov;117:192  IF ;  Mouse.   PubMed:33007486 [IF=6.986] Dai Shi. et al. Synthesis and Evaluation of 68Ga-NOTA-COG1410 Targeting to TREM2 of TAMs as a Specific PET Probe for Digestive Tumor Diagnosis. Anal Chem. 2022;94(9):3819–3830  ICC ;  Human.   PubMed:35195007 [IF=6.922] Shanping Wang. et al. Isosteviol Sodium Exerts Anti-Colitic Effects on BALB/c Mice with Dextran Sodium Sulfate-Induced Colitis Through Metabolic Reprogramming and Immune Response Modulation. J Inflamm Res. 2021; 14: 7107–7130  IF ;  Mouse.   PubMed:34992409 [IF=6.66] Evans, Elizabeth E., et al. "Antibody blockade of semaphorin 4D promotes immune infiltration into tumor and enhances response to other immunomodulatory therapies." Cancer Immunology Research (2015): canimm-0171.  IHC-P ;  Mouse.   PubMed:25614511 [IF=6.543] Wang Shanping. et al. Isosteviol Sodium Ameliorates Dextran Sodium Sulfate-Induced Chronic Colitis through the Regulation of Metabolic Profiling, Macrophage Polarization, and NF-κB Pathway. Oxid Med Cell Longev. 2022;2022:4636618  IF ;  Mouse.   PubMed:35126813 [IF=5.77] Sher Bahadur Poudel. et al. Excess Growth Hormone Triggers Inflammation-Associated Arthropathy, Subchondral Bone Loss, and Arthralgia. AM J PATHOL. 2023 Mar;:  IHC ;  Mouse.   PubMed:36870529 [IF=5.763] You Shuang. et al. Recombinant humanized collagen remodels endometrial immune microenvironment of chronic endometritis through macrophage immunomodulation. REGEN BIOMATER. 2023 Apr;:  IF ;  Rat.   PubMed:37122820 [IF=5.76] Das, Subhamoy, et al. "Syndesome Therapeutics for Enhancing Diabetic Wound Healing." Advanced Healthcare Materials (2016).  IHC-P ;  Mouse.   PubMed:27385307 [IF=5.714] Nancy K. El-Deeb. et al. Crosstalk between PI3K/AKT/KLF4 signaling and microglia M1/M2 polarization as a novel mechanistic approach towards flibanserin repositioning in parkinson's disease. INT IMMUNOPHARMACOL. 2022 Nov;112:109191  IHC ;  Rat.   PubMed:36055034 [IF=5.714] Shuling Zhang. et al. Methionine enkephalin suppresses lung cancer metastasis by regulating the polarization of tumor-associated macrophages and the distribution of myeloid-derived suppressor cells in the tumor microenvironment and inhibiting epithelial-mesenchymal transition. INT IMMUNOPHARMACOL. 2023 May;118:110064  IF ;  Mouse.   PubMed:36989897 [IF=5.714] Weam W. Ibrahim. et al. NLRP3 inflammasome inhibition and M1-to-M2 microglial polarization shifting via scoparone-inhibited TLR4 axis in ovariectomy/D-galactose Alzheimer's disease rat model. INT IMMUNOPHARMACOL. 2023 Jun;119:110239  IHC ;  Rat.   PubMed:37137264 [IF=5.7] Peruzzaro ST et al. Transplantation of mesenchymal stem cells genetically engineered to overexpress interleukin-10promotes alternative inflammatory response in rat model of traumatic brain injury. J Neuroinflammation. 2019 Jan 5;16(1):2.  IHC ;  Rat.   PubMed:30611291 [IF=5.606] Luo Ping. et al. IL-37 inhibits M1-like macrophage activation to ameliorate temporomandibular joint inflammation through the NLRP3 pathway. Rheumatology. 2020 Oct;59(10):3070-3080  WB,IF ;  Human.   PubMed:32417913
Research Area	immunology  Microbiology  Stem cells  Cell Surface Molecule  glycoprotein  lymphocyte  t-lymphocyte  b-lymphocyte
Immunogen Species	Rabbit
Clonality	Polyclonal
React Species	Human, Mouse, Rat,  (predicted: Dog, Pig, Cow, Sheep, )
Applications	WB=1:500-2000 ELISA=1:5000-10000 IHC-P=1:100-500 IHC-F=1:100-500 IF=1:100-500 （Paraffin sections need antigen repair） not yet tested in other applications. optimal dilutions/concentrations should be determined by the end user.
Theoretical molecular weight	31kDa
Detection molecular weight	72-74kDa
Cellular localization	The cell membrane
Form	Liquid
Concentration	1mg/ml
immunogen	KLH conjugated synthetic peptide derived from the middle of rat CD86: 140-175/313 <Extracellular>
Lsotype	IgG
Purification	affinity purified by Protein A
Buffer Solution	0.01M TBS(pH7.4) with 1% BSA, 0.03% Proclin300 and 50% Glycerol.
Storage	Shipped at 4℃. Store at -20 °C for one year. Avoid repeated freeze/thaw cycles.
Attention	This product as supplied is intended for research use only, not for use in human, therapeutic or diagnostic applications.
PubMed	PubMed
Product Detail	This gene encodes a type I membrane protein that is a member of the immunoglobulin superfamily. This protein is expressed by antigen-presenting cells, and it is the ligand for two proteins at the cell surface of T cells, CD28 antigen and cytotoxic T-lymphocyte-associated protein 4. Binding of this protein with CD28 antigen is a costimulatory signal for activation of the T-cell. Binding of this protein with cytotoxic T-lymphocyte-associated protein 4 negatively regulates T-cell activation and diminishes the immune response. Alternative splicing results in several transcript variants encoding different isoforms.[provided by RefSeq, May 2011]. Function: Receptor involved in the costimulatory signal essential for T-lymphocyte proliferation and interleukin-2 production, by binding CD28 or CTLA-4. May play a critical role in the early events of T-cell activation and costimulation of naive T-cells, such as deciding between immunity and anergy that is made by T-cells within 24 hours after activation. Isoform 2 interferes with the formation of CD86 clusters, and thus acts as a negative regulator of T-cell activation. Subunit: Homodimer. Interacts with MARCH8. Interacts with human herpesvirus 8 MIR2 protein (Probable). Interacts with adenovirus subgroup B fiber proteins and acts as a receptor for these viruses. Subcellular Location: Cell membrane; Single-pass type I membrane protein. Tissue Specificity: Expressed by activated B-lymphocytes and monocytes. Post-translational modifications: Polyubiquitinated; which is promoted by MARCH8 and results in endocytosis and lysosomal degradation. Similarity: Contains 1 Ig-like C2-type (immunoglobulin-like) domain. Contains 1 Ig-like V-type (immunoglobulin-like) domain. SWISS: O35531 Gene ID: 56822 Database links: Entrez Gene: 942 Human Entrez Gene: 56822 Rat Omim: 601020 Human SwissProt: P42081 Human Unigene: 171182 Human Unigene: 229570 Rat CD86是一个很重要要的辅助刺激分子，CD86作为CD28的辅助刺激分子，提供 T 细胞活化的辅助信号,它们之间的结合和随后介导的Signal transduction是 T 细胞和 APC 相互协作的重要分子基础。
Product Picture	Sample: Lane 1: HepG2 (Human) Cell Lysate at 30 ug Lane 2: U937 (Human) Cell Lysate at 30 ug Lane 3: Spleen (Rat) Lysate at 40 ug Lane 4: Spleen (Mouse) Lysate at 40 ug Lane 5: HL-60 (Human) Cell Lysate at 30 ug Primary: Anti-CD86 (SL1035R) at 1/1000 dilution Secondary: IRDye800CW Goat Anti-Rabbit IgG at 1/20000 dilution Predicted band size: 72-74 kD Observed band size: 72 kD Tissue/cell: Human esophageal carcinoma; 4% Paraformaldehyde-fixed and paraffin-embedded; Antigen retrieval: citrate buffer ( 0.01M, pH 6.0 ), Boiling bathing for 15min; Block endogenous peroxidase by 3% Hydrogen peroxide for 30min; Blocking buffer (normal goat serum,C-0005) at 37℃ for 20 min; Incubation: Anti-CD86/B7-2 Polyclonal Antibody, Unconjugated(SL1035R) 1:200, overnight at 4°C, followed by conjugation to the secondary antibody(SP-0023) and DAB(C-0010) staining Tissue/cell: rat lung tissue; 4% Paraformaldehyde-fixed and paraffin-embedded; Antigen retrieval: citrate buffer ( 0.01M, pH 6.0 ), Boiling bathing for 15min; Block endogenous peroxidase by 3% Hydrogen peroxide for 30min; Blocking buffer (normal goat serum,C-0005) at 37℃ for 20 min; Incubation: Anti-CD86/B7-2 Polyclonal Antibody, Unconjugated(SL1035R) 1:200, overnight at 4°C, followed by conjugation to the secondary antibody(SP-0023) and DAB(C-0010) staining Blank control: U937(blue). Primary Antibody: Rabbit Anti-CD86 antibody(SL1035R), Dilution: 1μg in 100 μL 1X PBS containing 0.5% BSA; Isotype Control Antibody: Rabbit IgG (orange) ,used under the same conditions. Secondary Antibody: Goat anti-rabbit IgG-PE(white blue), Dilution: 1:200 in 1 X PBS containing 0.5% BSA. Protocol The cells were fixed with 2% paraformaldehyde (10 min).Primary antibody (SL1035R, 1μg /1x10^6 cells) were incubated for 30 min on the ice, followed by 1 X PBS containing 0.5% BSA + 10% goat serum (15 min) to block non-specific protein-protein interactions. Then the Goat Anti-rabbit IgG/PE antibody was added into the blocking buffer mentioned above to react with the primary antibody at 1/200 dilution for 30 min on ice. Acquisition of 20,000 events was performed.

Cartpieces

• 
• 1

  1Delete

• 
• 5

  5Delete

• 
• S

  SDelete

• 
• R

  RDelete

• 
• +

  +Delete

• 
• 3

  3Delete

• Delete

• Delete

• 
• 1

  1Delete

• 
• 1

  1Delete

• 
• $

  $Delete

• 
• 0

  0Delete

• 
• 4

  4Delete

• 
• $

  $Delete

• 
• 0

  0Delete

• 
• 0

  0Delete

• 
• 1

  1Delete

• 
• C

  CDelete

• 
• C

  CDelete

• 

• Delete

• 
• i

  iDelete

• 
• i

  iDelete

• Delete

• 
• 1

  1Delete

• Delete

• 
• 1

  1Delete

• 
• 1

  1Delete

• 
• 0

  0Delete

• Delete

• 
• 2

  2Delete

• 
• 1

  1Delete

• 
• 0

  0Delete

• 
• 0

  0Delete

• 
• 0

  0Delete

• 
• 0

  0Delete

• 
• 0

  0Delete

• 
• 0

  0Delete

• 
• 1

  1Delete

• 
• 1

  1Delete

• Delete

• 
• -

  -Delete

• 
• -

  -Delete

• 
• 0

  0Delete

• Delete

• 
• t

  tDelete

• 
• 0

  0Delete

• 
• 0

  0Delete

• 
• 0

  0Delete

• 
• f

  fDelete

• Delete

• Delete

• Delete

• Delete

• Delete

• Delete

• Delete

• Delete

• Delete

• Delete

• Delete

• Delete

• Delete

• Delete

• 
• 4

  4Delete

• 
• $

  $Delete

• Delete

• 
• 0

  0Delete

• Delete

• Delete

• Delete

• 
• R

  RDelete

• 
• 5

  5Delete

• 
• A

  ADelete

Totalgoods,subtotals:￥Checkout